Acknowledgments
iSPOT-D is sponsored by Brain Resource Company Operations Pty Ltd. Brain Resource has established a Publication Committee, chaired by AJR, to provide transparent oversight and management of publication of results from the study, with the participation of study site investigators. We acknowledge the iSPOT-D Investigators Group, and the contributions of principal investigators at each site. We gratefully acknowledge the editorial support of Jon Kilner, MS, MA (Pittsburgh, PA, USA), the Scoring Server management by Donna Palmer, PhD (Brain Resource) and the monitoring support of PhaseForward.
Authors’ contributions
LMW made substantial contributions to conception and design of the trial, provided important intellectual content to the manuscript, was substantially involved in drafting and revising the manuscript, and gave final approval of the submitted version of the manuscript.
AJR made substantial contributions to conception and design of the trial, important intellectual content to the manuscript, was substantially involved in drafting and revising the manuscript, and gave final approval of the submitted version of the manuscript.
SHK made substantial contributions to conception of the trial, was substantially involved in drafting and revising the manuscript, and gave final approval of the submitted version of the manuscript.
SW made substantial contributions to the methods and statistical analysis for the trial, was substantially involved in drafting and revising the manuscript, and gave final approval of the submitted version of the manuscript.
NC made substantial contributions to the methods and statistical analysis for the trial, was substantially involved in drafting and revising the manuscript, and gave final approval of the submitted version of the manuscript.
CBN made substantial contributions to design of the trial, was substantially involved in drafting and revising the manuscript, and gave final approval of the submitted version of the manuscript.
AFS made substantial contributions to design of the trial, was substantially involved in drafting and revising the manuscript, and gave final approval of the submitted version of the manuscript.
EG conceptualized the design of the study, was substantially involved in drafting and revising the manuscript, and gave final approval of the submitted version of the manuscript.
Authors’ Information
LMW is founding Chair of the BRAINnet Foundation, a non-profit global consortium for integrative neuroscience (headquartered in California, USA), and Professor in Cognitive Neuropsychiatry at Sydney Medical School.
AJR is Vice Dean, Clinical Sciences at Duke-National University of Singapore Graduate medical School. Before this, he was Professor and Vice Chair in Clinical Sciences at Southwestern Medical Centre, US. AJR is an alumnus of Princeton University (biochemistry) and Doctor of Medicine from Columbia College of Physicians, with medical training at Northwestern University and psychiatry training at University of Pennsylvania. He has directed the largest treatment trial of depression ever conducted: the STAR*D trial http://www. star-d.org. AJR is Chair of the iSPOT-D Publication Committee.
SHK is Research Director for the American Foundation for Suicide Prevention, and Director on the board of the BRAINnet Foundation. He was the first Director of the Neuroscience Research Branch at the NIMH where he was responsible for initiating new research programs including Human Brain Imaging. SHK was founder of the International Neuroinformatics Coordinating Facility.
SW is a Professor in the Department of Epidemiology and Co-Director of the Epidemiology Data Center, University of Pittsburgh. His secondary appointment is in Psychiatry. He is an Associate Dean for Research in the Graduate School of Public Health.
CBN is Leonard M. Miller Professor and Chairman of the Department of Psychiatry and Behavioral Sciences, University of Miami. Before this, he built the Department of Psychiatry at Emory University School of Medicine in Atlanta into one of the top ten departments in the United States, as Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences.
AFS is the Chair of Stanford School of Medicine – Psychiatry and Behavioral Sciences.
EG was founding Director of the Brain Dynamics Centre (BDC), Sydney Medical School. He has founded the first standardized international database on the human brain.
Competing interests
LMW has received consulting fees and stock options in Brain Resource Ltd, and is a stock holder in Brain Resource Ltd. She has received Advisory Board fees from Pfizer.
AJR has received consulting fees from Advanced Neuromodulation Systems, AstraZeneca, Best Practice Project Management, Brain Resource Ltd, Bristol-Myers Squibb/Otsuka, Cyberonics, Gerson Lehrman Group, Jazz Pharmaceuticals, Magellan Health Services, Merck and Company, Neuronetics, Novartis Pharmaceuticals, Ono Pharmaceuticals, Organon, Otsuka Pharmaceuticals, Pamlab, Transcept Pharmaceuticals, Urban Institute, Wyeth Ayerst and University of Michigan. AJR has received fees for consulting and as speaker for consulting fees and honoraria from Cyberonics, Forest Pharmaceuticals, GlaxoSmithKline and Pfizer. He is a stock holder in Pfizer. AJR has received a stipend from Society of Biological Psychiatry (as Treasurer). He has author royalties from Guilford Publications, Healthcare Technology Systems and University of Texas Southwestern Medical Center.
SHK has received income as Research Director, from the American Foundation for Suicide Prevention. He has received fees and stock options as consultant, from Brain Resource Ltd. SHK has received consultant fees from Biomedical Synergy.
SRW has received fees as consultant from Cyberonic Inc, ImaRx Therapeutics Inc, Bristol-Myers Squibb Company, Organon, Case-Western University and Singapore Clinical Research Institute.
NJC has received income and stock options as senior statistician employee with Brain Resource Ltd.
CBN has received a Scientific Advisory Board/Board of Directors fee from AstraZeneca, PharmaNeuroboost, Forest Laboratories, NARSAD, Quintiles, Janssen/Ortho-McNeil, Mt. Cook Pharma Inc, George West Mental Health Foundation and NovaDel Pharma. He holds stock in Corcept, CeNeRx, ReVax, PharmaNeuroboost, Novadel Pharma. CBN has patents for Methods and devices for the transdermal delivery of lithium (US 6,375,990 BI) and Method to estimate serotonin and norepinephrine transporter occupancy after drug treatment using patient or animal serum (provisional filing April, 2001).
AFS has received fees as consultant from Brain Cells, CeNeRxm, CNS Response, Corcept, Glaxo-Smith Kline, Merck and Company, Neuronectics, PharmaNeuroBoost, Sanofi-Aventis and Takeda. He is a stock holder in Amnestix, Brain Cells, CeNeRx, Corpect, Forest, Merck and Company, Neurocrine, Pfizer, PharmaNeuroBoost, Somaxon and Synosis. AFS is cofounder of Corcept.
EG is founder and receives income as Chief Executive Officer and Chairman for Brain Resource Ltd. He has stock options in Brain Resource Ltd.